Group 1: Core Insights - UBS's in-depth research in China identifies two main industry themes for 2026: self-sufficiency and overseas expansion [1] - The research covered various sectors including technology, industrial, healthcare, consumer, and utilities, visiting over 100 companies and industry experts [1] - The report highlights a shift in investor interest, with capital goods, media entertainment, and real estate development seeing increased research focus, while semiconductor and automotive parts sectors experienced a decline [1] Group 2: Technology Sector Insights - The technology sector is a key focus, with advancements in self-sufficiency moving from isolated breakthroughs to industry-wide collaboration [2] - AI capital expenditure is expected to grow steadily in 2026, driven by strong demand for AI applications and local semiconductor production [3] - Despite uncertainties regarding H200 GPU imports, domestic supply chains are adapting through technology substitution and demand upgrades [3] Group 3: Semiconductor Developments - The localization of China's semiconductor industry is accelerating, with significant progress in advanced etching/ deposition equipment, advanced packaging, and high-end analog chips [4] - Capital expenditure for wafer fabrication equipment (WFE) is projected to grow by 10-15% annually, driven by capacity expansion in advanced logic and memory wafer fabs [4] - Domestic manufacturers anticipate a substantial increase in storage capital expenditure in 2026, aligning with a global upcycle in the storage industry [4] Group 4: Overseas Expansion Trends - Multiple industries, including industrial, biopharmaceuticals, and consumer goods, are focusing on overseas expansion as a key growth strategy [6] - In the industrial sector, overseas orders for AIDC and renewable energy storage equipment are increasing significantly [7] - The healthcare sector is also prioritizing global expansion, with biopharmaceutical companies actively pursuing international collaborations and local sales team development [9] Group 5: Key Recommendations - UBS recommends several core stocks in the technology and semiconductor sectors, including Northern Huachuang (advanced etching/ deposition), Changdian Technology (advanced packaging), and Horizon Robotics (edge AI) [5][12] - In the healthcare sector, companies like WuXi AppTec (CRO/CDMO) and 3SBio (biopharmaceuticals) are highlighted as key beneficiaries of global expansion [12] - The consumer sector sees recommendations for Jason Furniture (overseas expansion) and Leap Motor (new energy vehicles), while Gree Electric Appliances is advised to sell due to margin pressures [12] Group 6: Overall Industry Outlook - The report concludes that China's industrial development in 2026 will be characterized by a dual focus on self-sufficiency in technology and overseas expansion in various sectors [13] - The integration of these two themes is expected to enhance China's economic globalization, with technology supporting overseas expansion and vice versa [13] - Investment opportunities are identified in sectors with low crowding and improving fundamentals, as well as in high-growth areas like AI and semiconductors [13]

Core Viewpoint - The report from Guolian Minsheng Securities highlights the synergistic effects of small nucleic acid drugs and GLP-1 class drugs in the weight loss sector, suggesting they could become a "golden duo" for weight management [1][4]. Group 1: Drug Efficacy and Development - Arrowhead has reported promising initial weight loss results from two small nucleic acid drugs targeting INHBE and ALK7, with ARO-INHBE showing an average fat reduction of 9.9% and liver fat reduction of up to 38.6%, alongside a 3.6% increase in lean tissue [1]. - ARO-ALK7 demonstrated a dose-dependent average reduction of ALK7 mRNA by 88%, confirming the TRiM platform's ability to inhibit fat cell gene expression [1]. - Wave Life's WVE-007 targeting liver INHBE showed a 9.4% reduction in visceral fat and a 4.5% overall fat reduction after three months, with a 3.2% increase in lean body mass [3]. Group 2: Market Trends and Collaborations - Major pharmaceutical companies are increasingly investing in small nucleic acid drugs, with Eli Lilly committing $1.2 billion in collaboration with Saint Inbiotech for RNAi candidate drug development for metabolic diseases [3]. - Eli Lilly also invested $1 billion in HAYA's lncRNA platform for obesity and related metabolic disease treatments, while Novo Nordisk partnered with Replicate Bioscience for a $550 million project targeting obesity and type 2 diabetes [3]. - The speed of Chinese pharmaceutical companies in developing small nucleic acid drugs for weight loss is nearly on par with international counterparts, with several companies like Hengrui Medicine and Innovent Biologics actively pursuing this area [5]. Group 3: Investment Recommendations - The report suggests focusing on companies involved in small nucleic acid weight loss targets, including Hengrui Medicine, Chengdu Xian Dao, China National Pharmaceutical Group, East China Pharmaceutical, and others [6].

A股市场正在发生着翻天覆地的变化，3月2日，设立科创板并试点注册制主要制度规则正式发布，筹备了3个多月的科 创板正式开闸。近来也有不少港股公司用分拆、科创板+H股等方式回归A股。 北京办公软件转道科创板 金山软件(03888.HK)4月23日收盘后，扔下了一枚重磅：有关北京办公软件普通股建议分拆及上市事宜，经过审慎的 考虑，公司认为上海证券交易所科创板为更加适合的股票上市地。事实上，早在2017年5月，金山软件就已经动了将 WPS业务分拆赴A股上市的心思，当时北京办公软件瞄准的是深市创业板。 快到而立之年的WPS是中国国产可替代最具市场化的软件，近年来营收呈现加速增长态势。2018年内，办公软件全年 实现收入11.3亿，同比增速为56%，远高于2017年同比增速（32%）。金山办公收入模式主要有软件授权、服务订阅 和互联网广告三类，此前广告收入占比较大。 2018年11月，WPS安卓版的月活用户就已经突破了1亿，成为国产办公类手机软件中的冠军。"金山文档"月活突破 6900万，微信小程序用户突破8000万。此外，WPS还与阿里钉钉合作，将线上文档能力注入钉钉智能文档。 软件国产化自主可控为WPS企业版发展创造 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣東東陽光藥業股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06887 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 112,712,832 | RMB | | 1 | RMB | | 112,712,832 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 112,712,832 | RMB | | 1 | RMB | | 112,712,832 | | 2. 股份分類 ...

Core Viewpoint - The global antibacterial drug market is steadily expanding, driven by demand and technology, with an expected market size of approximately $56 billion by 2025. In contrast, the Chinese market is experiencing a slight decline due to volume-based procurement policies, with projected market sizes of 122.9 billion yuan in 2024 and about 118.9 billion yuan in 2025 [1][4]. Antibacterial Drug Industry Overview - Antibacterial drugs are commonly used for the treatment and prevention of infections caused by bacteria, mycoplasma, chlamydia, rickettsia, spirochetes, and fungi. However, misuse and over-prescription have led to significant antibiotic resistance issues [2][3]. - The Chinese antibacterial drug market has been stable but is facing a slight downward trend due to volume-based procurement policies. The total market size for systemic antibacterial drugs in Chinese medical institutions is projected to be 109.18 billion yuan in 2024, a decrease of 18.29 billion yuan from 2023 [4][5]. Antibacterial Drug Market Structure - In 2024, the sales distribution of antibacterial drugs in China is as follows: urban hospitals account for 52.2%, county hospitals 21.8%, township health centers 19.0%, and community health centers 6.9% [4][5]. - The global antibacterial drug market is expected to reach $57.1 billion by 2026, indicating continued growth in the coming years [3]. Industry Chain - The upstream of the antibacterial drug industry includes raw materials such as penicillin industrial salt, cephalosporin intermediates, quinolones, and erythromycin thiocyanate. The midstream involves the production of antibacterial drugs, while the downstream applications are in medical terminals and agricultural/animal use [5]. Industry Development Environment - The antibacterial drug sector is crucial for treating infectious diseases, but the misuse of these drugs has led to increased bacterial resistance, diminishing their effectiveness. To combat this, the government has implemented a series of regulations and policies aimed at managing and monitoring the use of antibacterial drugs [5]. Competitive Landscape - Major players in the domestic antibacterial drug market include companies like Chuaning Biological, Dongyang Sunshine Pharmaceutical, and Hansoh Pharmaceutical, focusing on antibiotic intermediates and finished drug production [6]. - Danuo Pharmaceutical, established in 2013, is nearing commercialization with innovative drug products targeting bacterial infections and related diseases. The company reported a net loss of 38 million yuan in Q1 2025, primarily due to high R&D expenditures [7]. - Chuaning Biological has established a large-scale industrial production system for antibiotic intermediates, achieving a revenue of 2.349 billion yuan in the first half of 2025, with 92.88% coming from pharmaceutical manufacturing [8]. Research and Development Trends - The focus of future antibacterial drug research will be on addressing antibiotic resistance challenges, with increased investment in innovative technologies expected to enhance R&D efficiency [8].

Market Performance - The Hong Kong stock market experienced fluctuations with the Hang Seng Index closing up by 361.43 points, a rise of 1.35% to 27,126.95 points [1] - The Hang Seng Tech Index increased by 28.73 points, up 0.5% to 5,754.72 points, while the National Enterprises Index rose by 97.67 points, a 1.07% increase to 9,244.88 points [1] - Major tech stocks showed mixed performance, with Alibaba up 2.85% and Tencent up 1.25%, while JD.com fell by 2.16% [1] Company News - China Power (02380.HK) reported a total electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual total of approximately 126 million MWh, down 1.27% [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Dongyang Sunshine Pharmaceutical (06887.HK) signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug development platform [3] - Weisheng Pharmaceutical-B (02561.HK) received approval from the National Medical Products Administration for the marketing license of its injectable growth hormone [4] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [5] - Heng Rui Pharmaceutical (01276.HK) received approval for clinical trials of its SHR-1049 injection [6] Institutional Insights - According to招商国际, the Hong Kong stock market is in a performance vacuum at the beginning of the year, with high growth expectations in the new economy driving market confidence [11] - 富国基金 suggests that the market is likely to maintain a volatile consolidation pattern, with core drivers stemming from global trade tensions and domestic economic recovery [11] - 华泰证券 emphasizes the potential for continued rebounds in the first quarter, focusing on sectors such as AI (semiconductors, software) and innovative pharmaceuticals [11] - 浙商国际 expresses optimism for sectors benefiting from policy support, including renewable energy, innovative pharmaceuticals, and AI technology [12]

Market Overview - The Hong Kong stock index showed an upward trend in early trading on January 27, with the Hang Seng Index rising by 1.07% to 27,053.05 points, the Hang Seng Tech Index increasing by 0.2% to 5,737.27 points, and the China Enterprises Index up by 0.86% to 9,225.77 points [1] - Major technology stocks exhibited mixed performance, with Alibaba up by 2.18%, Tencent Holdings up by 1.08%, JD.com down by 1.38%, and Meituan down by 0.51% [1] - Gold stocks continued to rise, with Zijin Mining and Zijin Gold International reaching historical highs, while insurance stocks were active, with AIA Group rising over 3% [1] Company News - China Power (02380.HK) reported a total electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual cumulative total of approximately 126 million MWh, down by 1.27% year-on-year [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Singularity National Peak (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug research and development platform [3] - Vison Pharmaceutical-B (02561.HK) received approval from the National Medical Products Administration for the marketing authorization application of injectable Long-acting Growth Hormone [4] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [5] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization of BRIMOCHOL PF for presbyopia treatment in Singapore and Vietnam through partnerships with AFT and Qianshou [5] - Heng Rui Pharmaceutical (01276.HK) received a clinical trial approval notice for SHR-1049 injection [6] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by relevant bondholder meetings [7] - Aibo Technology Holdings (08279.HK) entered into a technical service agreement with Hong Kong Gold Trading Co., Ltd. [8] - Future Data Group (08229.HK) signed a strategic cooperation framework agreement with Linghe Culture [9] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuan Zhi's initial public offering [10] Institutional Insights - According to招商国际, the Hong Kong stock market is currently in an earnings vacuum period, with high growth expectations for new economy sectors boosting market confidence. The appreciation of the RMB is favorable for Hong Kong stocks, and domestic policies are focusing on technological innovation and expanding domestic demand [11] - Citigroup believes that the outlook for Hong Kong stocks is better than that of A-shares, with optimism for 2026 supported by both southbound and foreign capital. However, potential risks include high overseas interest rates and corporate earnings falling short of expectations [11] - Huatai Securities noted that technology and cyclical "consumables" are expected to lead the recovery of Hong Kong stocks, with external pressures easing and domestic macro data stabilizing [11] - Guoyuan International suggests that the current environment may allow Hong Kong stocks to continue outperforming U.S. stocks, driven by low long-term valuation levels and potential recovery in domestic credit demand [12]

Core Viewpoint - Dongyangguang Pharmaceutical (600673) has entered a significant strategic partnership with Crystal Technology Holdings, focusing on the integration of AI and robotics in drug development, aiming to enhance R&D capabilities and commercialize new drug pipelines [1] Group 1: Strategic Partnership - Dongyangguang Pharmaceutical and Crystal Technology Holdings signed a strategic cooperation agreement on January 26, marking a major step in embracing the "AI + Robotics" R&D paradigm [1] - The partnership aims to establish a joint venture that leverages Crystal Technology's AI and robotics drug development platform alongside Dongyangguang's extensive experience in multi-target R&D data and pipeline development [1] Group 2: Investment and Goals - Dongyangguang Pharmaceutical is expected to invest several hundred million yuan in this collaboration, with the goal of creating an industry-leading AI drug development engine [1] - The companies aim to build a "pipeline co-creation + technology win-win" multi-dimensional profit model, focusing on comprehensive cooperation in technology and new drug pipeline development [1]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has signed a significant strategic cooperation agreement with Crystal Technology Holdings, marking a strategic leap towards embracing "AI + Robotics" in drug development [1] Group 1: Strategic Partnership - The collaboration aims to establish a joint venture that integrates Crystal Technology's AI + Robotics drug development platform with Dongyang Sunshine's extensive experience in multi-target research data and pipeline development [1] - The partnership will involve the creation of an AI + Robotics joint laboratory and the development of non-clinical drug models to address long-standing challenges in drug research [1] Group 2: Financial Commitment and Goals - Dongyang Sunshine is expected to invest several hundred million yuan in this collaboration, with the goal of building an industry-leading AI drug development engine and achieving technology export [1] - The companies aim to create a diversified profit model through "pipeline co-creation + technology co-win" [1]

Group 1 - Strategic partnership established between Dongyangguang Pharmaceutical (06887) and Shenzhen Jingtai Technology on January 26, 2026 [1] - Joint venture to create an AI-driven drug research and development platform, focusing on innovative drug development for autoimmune diseases [1] - Development of PB-PK predictive large model and promotion of Dongyangguang's proprietary "HEC-SynAI drug synthesis model" and "HEC-PharmAI formulation model" [1] Group 2 - Innovation in business model through the establishment of an AI supercomputing platform, creating a "Model as a Service" (MaaS) business model [1] - Dongyangguang Pharmaceutical has 150 approved drugs and over 100 drugs in research, including nearly 50 first-class innovative drugs, leading in patent numbers among domestic pharmaceutical companies from 2014 to 2023 [1] - As of the announcement date, a formal agreement has not yet been signed, indicating uncertainty in the partnership [1]